Despite a slight revenue decline, CRL focuses on strategic initiatives and cost savings to drive long-term growth and ...

The saliva-based CRL Rapid Response Test is focused on getting businesses and schools back to work. Clinical Reference Laboratories CEO Robert Thompson joins Jill Malandrino on Nasdaq #TradeTalks to ...

The FDA's policy of publishing CRLs aims to enhance transparency and accelerate drug development by providing early access to regulatory feedback. The release of CRLs has elicited mixed reactions, ...

The troubles keep piling up for Immunomedics. The New Jersey-based biotech, which has gone through a failed tie-up deal, boardroom cleansing and FDA Form 483 issues, reported that it has received a ...